Rep. Ro Khanna sold Incyte (INCY)
Rep. Ro Khanna (D-CA-17) · $1K–$15K · traded Oct 7, 2026
- Transaction
- Sold
- Amount
- $1K–$15K
- Owner
- Spouse
- Traded
- Oct 7, 2026
- Disclosed
- Nov 5, 2026
- Days to disclose
- 29
- Asset type
- Stock
- As filed
- Incyte Corp
- Industry
- Biotechnology · Healthcare
Other trades in this filing
All of Khanna's trades →- Nov 5, 2026$1K–$15K
Bought The Cooper Companies COO
$1K–$15K · Traded Oct 30, 2026 · disclosed Nov 5, 2026 · Spouse
- Nov 5, 2026$1K–$15K
$1K–$15K · Traded Oct 30, 2026 · disclosed Nov 5, 2026 · Spouse
- Nov 5, 2026$1K–$15K
Sold Zimmer Biomet Holdings ZBH
$1K–$15K · Traded Oct 30, 2026 · disclosed Nov 5, 2026 · Spouse
Traded 5 days before earnings - Nov 5, 2026$1K–$15K
Sold Zimmer Biomet Holdings ZBH
$1K–$15K · Traded Oct 30, 2026 · disclosed Nov 5, 2026 · Dependent
Traded 5 days before earnings - Nov 5, 2026$1K–$15K
$1K–$15K · Traded Oct 29, 2026 · disclosed Nov 5, 2026 · Spouse
- Nov 5, 2026$1K–$15K
Sold Microchip Technology MCHP
$1K–$15K · Traded Oct 28, 2026 · disclosed Nov 5, 2026 · Dependent
Traded 8 days before earnings - Nov 5, 2026$1K–$15K
$1K–$15K · Traded Oct 28, 2026 · disclosed Nov 5, 2026 · Dependent
- Nov 5, 2026$1K–$15K
$1K–$15K · Traded Oct 28, 2026 · disclosed Nov 5, 2026 · Dependent
Traded 7 days before earnings - Nov 5, 2026$1K–$15K
$1K–$15K · Traded Oct 28, 2026 · disclosed Nov 5, 2026 · Dependent
- Nov 5, 2026$1K–$15K
$1K–$15K · Traded Oct 28, 2026 · disclosed Nov 5, 2026 · Dependent
- Nov 5, 2026$1K–$15K
$1K–$15K · Traded Oct 28, 2026 · disclosed Nov 5, 2026 · Spouse
- Nov 5, 2026$1K–$15K
Sold Graphic Packaging Holding Company GPK
$1K–$15K · Traded Oct 28, 2026 · disclosed Nov 5, 2026 · Spouse
Traded 6 days before earnings - Nov 5, 2026$1K–$15K
Sold Graphic Packaging Holding Company GPK
$1K–$15K · Traded Oct 28, 2026 · disclosed Nov 5, 2026 · Dependent
Traded 6 days before earnings - Nov 5, 2026$1K–$15K
$1K–$15K · Traded Oct 27, 2026 · disclosed Nov 5, 2026 · Spouse
Traded 1 day before earnings - Nov 5, 2026$1K–$15K
Sold Graphic Packaging Holding Company GPK
$1K–$15K · Traded Oct 27, 2026 · disclosed Nov 5, 2026 · Spouse
Traded 7 days before earnings - Nov 5, 2026$1K–$15K
Sold Graphic Packaging Holding Company GPK
$1K–$15K · Traded Oct 27, 2026 · disclosed Nov 5, 2026 · Dependent
Traded 7 days before earnings - Nov 5, 2026$1K–$15K
$1K–$15K · Traded Oct 26, 2026 · disclosed Nov 5, 2026 · Spouse
Traded 2 days before earnings - Nov 5, 2026$1K–$15K
$1K–$15K · Traded Oct 26, 2026 · disclosed Nov 5, 2026 · Dependent
Traded 2 days before earnings - Nov 5, 2026$1K–$15K
$1K–$15K · Traded Oct 23, 2026 · disclosed Nov 5, 2026 · Spouse
- Nov 5, 2026$1K–$15K
Sold FactSet Research Systems FDS
$1K–$15K · Traded Oct 22, 2026 · disclosed Nov 5, 2026 · Spouse
Recent Congress trades in INCY
- Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Sep 4, 2026 · disclosed Oct 7, 2026 · Spouse
- May 31, 2025$1K–$15K
Rep. Robert P. Bresnahan, Jr. (R-PA-8)
$1K–$15K · Traded May 15, 2025 · disclosed May 31, 2025
- Nov 8, 2023$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Oct 10, 2023 · disclosed Nov 8, 2023 · Spouse
- Nov 8, 2023$1K–$15K
- Apr 17, 2023$1K–$15K
Rep. Daniel S. Goldman (D-NY-10)
$1K–$15K · Traded Mar 6, 2023 · disclosed Apr 17, 2023
- Dec 8, 2018$1K–$15K
Sen. Shelley Moore Capito (R-WV)
$1K–$15K · Traded Nov 12, 2018 · disclosed Dec 8, 2018 · Spouse
- Oct 6, 2017$1K–$15K
Sen. Shelley Moore Capito (R-WV)
$1K–$15K · Traded Sep 8, 2017 · disclosed Oct 6, 2017 · Spouse
Company context for INCY
Recent records for the company. These may have been published before or after this trade; compare the dates before drawing a connection.
INCY: 10-Q financial filing
Filed 10-Q for an event or period dated 2026-09-30. Read the company report for its disclosures.
1 congressional household disclosed purchases in the past 90 days. See the trades
INCY: Financial results
Filed 8-K for an event or period dated 2026-10-29. Financial results.
1 congressional household disclosed purchases in the past 90 days. See the trades
Issuance of Priority Review Voucher; Rare Pediatric Disease Product; ATEBRIOZ (Zilurgisertib)
The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that ATEBRIOZ (zilurgisertib), approved September 25, 2026, manufactured by Incyte Corporation meets the criteria for a priority review voucher.
Public: Oct 28, 2026Original source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
From a periodic transaction report filed under the STOCK Act. Amounts are the ranges members report. Nothing here is investment advice.